IFNG and myeloid sarcoma: The observed inhibitory effects of evobrutinib on IFN-γ– and CpG-ODN–mediated class switching in B cells is relevant, given their enhanced responsiveness to such signals and capacity to serve as potent antigen-presenting cells in MS (4, 8, 12).